Description
IBM Aspera Faspex 5.0.0 through 5.0.9 could allow a user with access to the package to obtain sensitive information through a directory listing.
Published: 2024-09-05
Score: 6.5 Medium
EPSS: < 1% Very Low
KEV: No
Impact: n/a
Action: n/a
AI Analysis

Analysis and contextual insights are available on OpenCVE Cloud.

Remediation

No vendor fix or workaround currently provided.

Additional remediation guidance may be available on OpenCVE Cloud.

Tracking

Sign in to view the affected projects.

Advisories
Source ID Title
EUVD EUVD EUVD-2024-41303 IBM Aspera Faspex 5.0.0 through 5.0.9 could allow a user with access to the package to obtain sensitive information through a directory listing.
History

Fri, 06 Sep 2024 13:00:00 +0000

Type Values Removed Values Added
Weaknesses NVD-CWE-Other
CPEs cpe:2.3:a:ibm:aspera_faspex:*:*:*:*:*:*:*:*

Thu, 05 Sep 2024 16:30:00 +0000

Type Values Removed Values Added
Metrics ssvc

{'options': {'Automatable': 'no', 'Exploitation': 'none', 'Technical Impact': 'partial'}, 'version': '2.0.3'}


Thu, 05 Sep 2024 15:45:00 +0000

Type Values Removed Values Added
Description IBM Aspera Faspex 5.0.0 through 5.0.9 could allow a user with access to the package to obtain sensitive information through a directory listing.
Title IBM Aspera Faspex information disclosure
First Time appeared Ibm
Ibm aspera Faspex
Weaknesses CWE-548
CPEs cpe:2.3:a:ibm:aspera_faspex:5.0.0:*:*:*:*:*:*:*
cpe:2.3:a:ibm:aspera_faspex:5.0.9:*:*:*:*:*:*:*
Vendors & Products Ibm
Ibm aspera Faspex
References
Metrics cvssV3_1

{'score': 6.5, 'vector': 'CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N'}


Subscriptions

Ibm Aspera Faspex
cve-icon MITRE

Status: PUBLISHED

Assigner: ibm

Published:

Updated: 2024-09-05T15:47:08.719Z

Reserved: 2024-08-21T19:11:14.497Z

Link: CVE-2024-45096

cve-icon Vulnrichment

Updated: 2024-09-05T15:47:03.670Z

cve-icon NVD

Status : Analyzed

Published: 2024-09-05T16:15:07.810

Modified: 2024-09-06T12:34:17.957

Link: CVE-2024-45096

cve-icon Redhat

No data.

cve-icon OpenCVE Enrichment

No data.

Weaknesses